神經生物標記市場機會、成長動力、產業趨勢分析及 2025 年至 2034 年預測

2024 年，全球神經生物標記市場估值為 95 億美元，預計 2025 年至 2034 年間將以 10.9% 的年複合成長率(CAGR) 成長。的盛行率不斷上升，推動市場成長的關鍵因素。神經系統疾病的增加主要歸因於人口老化，阿茲海默症在老年人中變得越來越常見。

這些疾病的激增刺激了對個人化醫療的需求，因為量身定做的治療可以為患者帶來更好的結果。基因組學、蛋白質組學和成像技術的進步也在神經系統疾病的早期檢測和診斷中發揮關鍵作用。識別大腦或血液中特定蛋白質、基因或代謝物的生物標記物顯著提高了診斷準確性，使醫療保健專業人員能夠提供及時有效的治療。

神經生物標記是評估各種神經系統疾病的存在和進展的關鍵指標。這些生物標記可以是與阿茲海默症、帕金森氏症、多發性硬化症和自閉症譜系障礙等疾病相關的分子、基因或其他物質。市場按產品類型分為蛋白質體學、基因組學、代謝組學、影像和其他生物標記。其中，在液相層析質譜 (LC-MS/MS) 和多重檢測等技術進步的推動下，蛋白質體生物標記細分市場在 2024 年佔據市場主導地位，佔 31 億美元。

這些創新提高了蛋白質體學測試的靈敏度和可靠性，從而可以更早地檢測並更好地管理神經系統疾病。此外，對精準醫學的日益關注預計將增加臨床環境和藥物開發中對蛋白質組生物標記的需求。

按疾病類型分類，阿茲海默症在 2024 年佔據最大市場佔有率，達到 45.5%，反映出對早期診斷解決方案的迫切需求。基於血液的生物標記已成為傳統腦脊髓液測試的侵入性較小且更具成本效益的替代方案，進一步推動了市場成長。

以2024 年的最終用途計算，醫院和診所領域在市場中佔據主導地位，預計到2034 年將達到110 億美元。患者的治療效果。政府支持、研究資助以及與私人組織的合作也正在加速將生物標記融入常規臨床實踐。

在北美，美國在 2024 年佔據神經生物標記市場的重要佔有率，價值 37 億美元。該地區受益於技術進步、對精準醫療的日益關注以及對針對個人遺傳和疾病特徵的個人化治療的不斷成長的需求。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

• 產業生態系統分析
• 產業影響力
  • 成長動力
    • 神經系統疾病盛行率增加
    • 生物標記研究進展
    • 採用個人化醫療
    • 患者和醫療保健提供者對神經系統疾病的認知不斷提高
  • 產業陷阱與挑戰
    • 生物標記檢測成本高
    • 缺乏標準化
• 成長潛力分析
• 未來市場趨勢
• 監管環境
• 波特的分析
• PESTEL分析

第 4 章：競爭格局

• 介紹
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 戰略儀表板

第 5 章：市場估計與預測：按產品類型，2021 - 2034 年

• 主要趨勢
• 蛋白質體生物標記
• 基因組生物標記
• 代謝組生物標記
• 影像學
• 其他生物標記類型

第 6 章：市場估計與預測：按疾病類型，2021 - 2034 年

• 主要趨勢
• 阿茲海默症
• 帕金森氏症
• 自閉症譜系障礙
• 癲癇
• 其他疾病

第 7 章：市場估計與預測：按最終用途，2021 - 2034 年

• 主要趨勢
• 醫院和診所
• 研究實驗室
• 生物製藥公司
• 其他最終用戶

第 8 章：市場估計與預測：按地區分類，2021 - 2034 年

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 9 章：公司簡介

• Abbott Laboratories
• ACOBIOM
• Alseres Pharmaceuticals
• Banyan Biomarkers
• Bio-Rad Laboratories
• DiaGenic ASA
• Johnson & Johnson Services
• Merck KGaA
• QIAGEN
• Quanterix
• Rules-Based Medicine
• Thermo Fisher Scientific

The Global Neurological Biomarkers Market was valued at USD 9.5 billion in 2024 and is expected to grow at a compound annual growth rate (CAGR) of 10.9% between 2025 and 2034. The rising prevalence of neurodegenerative disorders, such as Alzheimer's and Parkinson's disease, is a key factor driving market growth. This increase in neurological conditions is primarily attributed to the aging population, with Alzheimer's disease becoming increasingly common among older adults.

The surge in these disorders has fueled demand for personalized medicine, as tailored treatments can lead to better outcomes for patients. Advancements in genomics, proteomics, and imaging technologies are also playing a pivotal role in the early detection and diagnosis of neurological diseases. Biomarkers that identify specific proteins, genes, or metabolites in the brain or blood have significantly enhanced diagnostic accuracy, enabling healthcare professionals to provide timely and effective treatment.

Neurological biomarkers serve as critical indicators for assessing the presence and progression of various neurological diseases. These biomarkers can be molecules, genes, or other substances linked to conditions such as Alzheimer's, Parkinson's, multiple sclerosis, and autism spectrum disorders. The market is segmented by product type into proteomic, genomic, metabolomic, imaging, and other biomarkers. Among these, the proteomic biomarker segment led the market in 2024, accounting for USD 3.1 billion, driven by advancements in technologies like liquid chromatography-mass spectrometry (LC-MS/MS) and multiplex assays.

These innovations have improved the sensitivity and reliability of proteomic tests, allowing for earlier detection and better management of neurological conditions. Additionally, the growing focus on precision medicine is expected to boost demand for proteomic biomarkers in both clinical settings and drug development.

By disease type, Alzheimer's disease held the largest market share of 45.5% in 2024, reflecting the urgent need for early diagnostic solutions. Blood-based biomarkers have emerged as a less invasive and more cost-effective alternative to traditional cerebrospinal fluid tests, further driving market growth.

The hospitals and clinics segment dominated the market by end use in 2024 and is projected to reach USD 11 billion by 2034. These facilities are increasingly adopting non-invasive biomarker diagnostics, improving patient outcomes through personalized care. Government support, funding for research, and collaborations with private organizations are also accelerating the integration of biomarkers into routine clinical practice.

In North America, the U.S. held a significant share of the neurological biomarkers market in 2024, valued at USD 3.7 billion. The region benefits from technological advancements, increased focus on precision medicine, and a rising demand for personalized therapies tailored to individual genetic and disease profiles.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of neurological disorders
    • 3.2.1.2 Advancement in biomarker research
    • 3.2.1.3 Adoption of personalized medicine
    • 3.2.1.4 Rising awareness among patients and healthcare providers of neurological disorders
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of biomarker testing
    • 3.2.2.2 Lack of standardization
• 3.3 Growth potential analysis
• 3.4 Future market trends
• 3.5 Regulatory landscape
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Proteomic biomarkers
• 5.3 Genomic biomarkers
• 5.4 Metabolomic biomarkers
• 5.5 Imaging
• 5.6 Other biomarker types

Chapter 6 Market Estimates and Forecast, By Disease Type, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Alzheimer's disease
• 6.3 Parkinson's disease
• 6.4 Autism spectrum disorders
• 6.5 Epilepsy
• 6.6 Other diseases

Chapter 7 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals and clinics
• 7.3 Research laboratories
• 7.4 Biopharmaceutical companies
• 7.5 Other end users

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 India
  • 8.4.3 Japan
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 Abbott Laboratories
• 9.2 ACOBIOM
• 9.3 Alseres Pharmaceuticals
• 9.4 Banyan Biomarkers
• 9.5 Bio-Rad Laboratories
• 9.6 DiaGenic ASA
• 9.7 Johnson & Johnson Services
• 9.8 Merck KGaA
• 9.9 QIAGEN
• 9.10 Quanterix
• 9.11 Rules-Based Medicine
• 9.12 Thermo Fisher Scientific